Corcept Therapeutics (CORT) Other Accumulated Expenses (2010 - 2026)

Corcept Therapeutics has reported Other Accumulated Expenses for 15 years, with the latest figure at $21.6 million in Q2 2026.

• Quarterly Other Accumulated Expenses fell 25.55% year-over-year to $21.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $21.6 million (down 25.55% YoY) and the FY2025 annual result came in at $34.0 million, changed 0.25% from the prior year.
• Other Accumulated Expenses declined to $21.6 million in Q2 2026 per CORT's latest filing, from $34.0 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $34.0 million in Q4 2025 and troughed at $13.8 million in Q2 2022.
• A 5-year average of $23.8 million and a median of $21.8 million in 2024 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2026: Other Accumulated Expenses soared 58.78% in 2024, then fell 25.55% in 2026.
• Over 5 years, Other Accumulated Expenses stood at $14.6 million in 2022, then soared by 46.37% to $21.3 million in 2023, then jumped by 58.78% to $33.9 million in 2024, then advanced by 0.25% to $34.0 million in 2025, then slumped by 36.3% to $21.6 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $21.6 million, $34.0 million, and $28.3 million for Q2 2026, Q4 2025, and Q3 2025 respectively.